This challenge is fair, but to some extent this study seeks to address the absence of direct individual level needs data by using diagnostic information.
Although the non-genomic function of ER α in the absence of BRCA1 needs further investigation, our data suggest that IGF-1 might be produced at higher levels in breast cancers with a loss of BRCA1 function, which may induce a 'positive-feedback loop' in activating IGF-1R/PI3K/AKT/ER α signaling.
In the absence of experimental data, this issue needs to be treated in a more balanced way, and both possibilities kept open.
In the absence of the data and computer power needed to run a dynamic model, the approach used in the current evaluation provide an alternative for countries willing to compare alternative vaccination strategies.
Greater focus on these areas is essential for decision makers to be able to identify geographical regions and/or groups of people among whom health inequities exist and where extra attention is therefore needed; and in the absence of good data, progress towards addressing the inequities will inevitably be compromised.
Frequently, the absence of initial data and the need of fulfilling different types of restrictions (some of them prone to subjectivity) turn design processes into real optimization problems where the classical methods frequently fail and for which the most current techniques based on neural networks, genetic algorithms, fuzzy theory, chaos theory, etc. are indispensable.
The design of these programmes and many others are impaired by the absence of data and by bad data on women and girls.
Furthermore, little data are available in the literature concerning the absence of or need for secondary and tertiary care infrastructure or services, potentially owing to the absence of these services in infrastructure assessments such as those included in our review.
Nonetheless, the absence of these data highlight the critical need for systematic collection of high-resolution socioeconomic data alongside the types of environmental and hospital and health information presented here.
How do we make the best possible decision right now, in the absence of all the data we need?" She paused for a long moment, then said, "My biggest fear is that we are just doing too little too late, and that even if we move sooner, we are not lowering amyloid sufficiently.
